NL-OMON33063招募中2 期
Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer - temsirolimus-RCC-imaging
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. patients with histologically confirmed, advanced (stage IV or recurrent disease) RCC who have received at least one prior angiogenesis inhibitor for their disease.
- •2. Karnofsky performance status >= 70.
- •3. At least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter >= 10-mm when measured by spiral computerized tomography (CT, 5-mm slice thickness contiguous)
- •4. Age >= 18 years.
- •5. Absolute neutrophil count (ANC) >= 1.5 x 109/L (1500 cells/mm3), platelet count >= 100 x 109/L (100,000 cells/ mm3), hemoglobin >= 8.0 g/dL (5.0 mmol/L).
- •6. Adequate renal function (serum creatinine >= 1.5 times the ULN) or creatinin clearance of >= 50 ml/min
- •7. Adequate hepatic function (bilirubin <= 1.5 times the ULN, aspartate transaminase (AST) <= 3 times the ULN [<= 5 times the ULN if liver metastases are present]).
- •8. Fasting serum cholesterol <= 350 mg/dL (9.0 mmol/L), triglycerides <= 400 mg/dL (4.56 mmol/L).
- •9. Subjects receiving cytochrome P450 (CYP) 3A4 inducers or inhibitors must be on stable doses for at least 1 week prior to randomization.
- •10. Life expectancy of at least 8 weeks.
- •11. Negative pregnancy test for female patients of childbearing potential
- •12. Women and men enrolled into this trial must use adequate birth control measures during the course of the trial and must continue for 3 months after the last dose of temsirolimus.
- •13.Signed and dated written informed consent form
排除标准
- •1. Subjects with central nervous system (CNS) metastases. Subjects with a prior history of CNS metastases will be eligible if the screening magnetic resonance imaging (MRI)/CT (with contrast) indicates no residual disease.
- •2. Prior investigational therapy/agents within 2 weeks of randomization.
- •3. Prior treatment with a mTOR inhibitor
- •4. History of other prior malignancy in past 5 years, other than basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
- •5. Not recovered from prior surgery and/or surgery or radiation therapy within 4 weeks of randomization.
- •6. Immunocompromised subjects, including subjects known to be human immunodeficiency virus (HIV) positive, hepatitis B positive, or hepatitis C positive.
- •7. Active infection or serious intercurrent illness.
- •8. Presence of unstable angina or myocardial infarction within the previous 6 months (prior to screening), use of ongoing maintenance therapy for life-threatening arrhythmia, known pulmonary hypertension, or pneumonitis.
- •9. Pregnant or nursing women, women who are of childbearing potential who are not using an effective contraceptive method, or men with partners of childbearing potential who are not using an effective contraceptive method. (A woman of childbearing potential is defined as a woman who is biologically capable of becoming pregnant.)
- •10. Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer - temsirolimus-RCC-imagingadvanced (stage IV or recurrent disease) RCCEUCTR2009-012802-38-NLniversity Medical Centre Nijmegen St Radboud
进行中（未招募）
1 期
Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique. - VESTOREUCTR2009-011049-15-FRInstitut Bergonié - Département d’Oncologie Médicale
进行中（未招募）
不适用
A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma - Temsirolimus in PZNSPatients with refractory and recidivated primary CNS lymphomaEUCTR2009-011277-33-DECharité - University Hospital of Berlin
进行中（未招募）
不适用
Activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial carcinomaplatinum-refractory ovarian carcinoma or advanced endometrial carcinomaMedDRA version: 15.1Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000299-33-DEAGO Research GmbH
进行中（未招募）
1 期
/AAdvanced hormone - and chemotherapy - resistant prostate cancerEUCTR2011-002087-24-GRHellenic Oncology Research Group (HORG)